List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8604539/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, The, 2016, 388, 2997-3005.	6.3	435
2	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, The, 2013, 14, 989-998.	5.1	246
3	Prognostic factors for patients with hepatic metastases from breast cancer. British Journal of Cancer, 2003, 89, 284-290.	2.9	177
4	Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treatment Reviews, 2000, 26, 91-102.	3.4	159
5	Brain metastases from breast cancer: identification of a high-risk group. Clinical Oncology, 2004, 16, 345-349.	0.6	143
6	Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. British Journal of Cancer, 2004, 90, 590-594.	2.9	122
7	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncology, The, 2021, 22, e327-e340.	5.1	121
8	Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features. British Journal of Cancer, 2003, 89, 660-665.	2.9	117
9	The assessment and management of older cancer patients: A SIOG surgical task force survey on surgeons' attitudes. European Journal of Surgical Oncology, 2016, 42, 297-302.	0.5	117
10	Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. European Journal of Surgical Oncology, 2009, 35, 113-122.	0.5	82
11	Fulvestrant - A Novel Endocrine Therapy for Breast Cancer. Current Medicinal Chemistry, 2010, 17, 902-914.	1.2	73
12	Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Lancet Oncology, The, 2021, 22, e29-e36.	5.1	71
13	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research, 2018, 24, 6594-6610.	3.2	70
14	Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. British Journal of Cancer, 2013, 108, 1042-1051.	2.9	65
15	Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. Journal of Geriatric Oncology, 2020, 11, 1190-1198.	0.5	60
16	A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer—Final results at 20-year follow-up. Critical Reviews in Oncology/Hematology, 2011, 78, 260-264.	2.0	59
17	The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. European Journal of Cancer, 1997, 33, 1774-1779.	1.3	57
18	Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study. PLoS ONE, 2014, 9, e87027.	1.1	55

#	Article	IF	CITATIONS
19	Endoscopic Stenting for Malignant Biliary Obstruction. Archives of Surgery, 1995, 130, 204.	2.3	54
20	Endocrine therapy for breast cancer: an overview. Breast, 2007, 16, 327-343.	0.9	52
21	The effects of gefitinib in tamoxifenâ€resistant and hormoneâ€insensitive breast cancer: A phase II study. International Journal of Cancer, 2010, 126, 1806-1816.	2.3	51
22	Pathological features of primary breast cancer in the elderly based on needle core biopsies—A large series from a single centre. Critical Reviews in Oncology/Hematology, 2008, 67, 263-267.	2.0	49
23	Relationship between HbA _{1c} and cancer in people with or without diabetes: a systematic review. Diabetic Medicine, 2016, 33, 1013-1025.	1.2	49
24	A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Annals of Oncology, 2012, 23, 2296-2300.	0.6	48
25	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2991-3002.	3.2	46
26	Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. British Journal of Cancer, 2011, 104, 1393-1400.	2.9	44
27	Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ. European Journal of Surgical Oncology, 1997, 23, 343-347.	0.5	42
28	Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma <i>In situ</i> Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial. Clinical Cancer Research, 2010, 16, 1605-1612.	3.2	42
29	Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. Oncology and Therapy, 2020, 8, 1-11.	1.0	37
30	Can computerised tomography replace bone scintigraphy in detecting bone metastases from breast cancer? A prospective study. Breast, 2008, 17, 98-103.	0.9	36
31	Comprehensive geriatric assessment for older women with early breast cancer – a systematic review of literature. World Journal of Surgical Oncology, 2012, 10, 88.	0.8	36
32	Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clinical Radiology, 2004, 59, 1094-1098.	0.5	35
33	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 2017, 8, 14897-14911.	0.8	35
34	Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. European Journal of Cancer, 2010, 46, 2936-2942.	1.3	34
35	The potential value of comprehensive geriatric assessment in evaluating older women with primary operable breast cancer undergoing surgery or non-operative treatment — A pilot study. Journal of Geriatric Oncology, 2015, 6, 46-51.	0.5	34
36	Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Research and Treatment, 1997, 45, 219-224.	1.1	33

#	Article	IF	CITATIONS
37	How relevant is breast cancer screening in the Asia/Pacific region?. Breast, 2007, 16, 113-119.	0.9	32
38	Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast, 2011, 20, 215-219.	0.9	32
39	Neoadjuvant endocrine treatment in primary breast cancer – Review of literature. Breast, 2009, 18, 339-344.	0.9	30
40	Biological Characteristics and Clinical Outcome of Triple Negative Primary Breast Cancer in Older Women – Comparison with Their Younger Counterparts. PLoS ONE, 2014, 9, e100573.	1.1	30
41	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncology and Therapy, 2018, 6, 141-156.	1.0	30
42	MANAGEMENT OF CYCLICAL MASTALGIA IN ORIENTAL WOMEN: PIONEER EXPERIENCE OF USING GAMOLENIC ACID (EFAMAST ®) IN ASIA. Australian and New Zealand Journal of Surgery, 1999, 69, 492-494.	0.2	29
43	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2â^' Primary Breast Cancer. Clinical Cancer Research, 2020, 26, 4242-4249.	3.2	29
44	Locally advanced primary breast cancer. European Journal of Cancer, 2001, 37, 2331-2338.	1.3	28
45	Fulvestrant in Advanced Male Breast Cancer. Breast Cancer Research and Treatment, 2007, 101, 123-123.	1.1	28
46	Early primary breast cancer in the elderly – Pattern of presentation and treatment. Surgical Oncology, 2011, 20, 7-12.	0.8	28
47	Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 619-628.	1.1	27
48	Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer. European Journal of Surgical Oncology, 2015, 41, 1234-1242.	0.5	26
49	Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices. British Journal of Surgery, 2021, 108, 499-510.	0.1	26
50	Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic. Annals of Oncology, 2012, 23, 1465-1471.	0.6	25
51	Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and longâ€ŧerm effects based on sequential biopsies. International Journal of Cancer, 2016, 138, 146-159.	2.3	25
52	Bridging the age gap in breast cancer: evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial. BMJ Open, 2017, 7, e015133.	0.8	25
53	Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). Clinical Cancer Research, 2020, 26, 1574-1585.	3.2	25
54	BQ323636.1, a Novel Splice Variant to <i>NCOR</i> 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3681-3691.	3.2	23

#	Article	IF	CITATIONS
55	Successful management of elderly breast cancer patients treated without radiotherapy. World Journal of Surgical Oncology, 2007, 5, 62.	0.8	21
56	Variation in Telangiectasia Predisposing Genes IsÂAssociated With Overall Radiation Toxicity. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1031-1036.	0.4	20
57	The balance of clinician and patient input into treatment decisionâ€making in older women with operable breast cancer. Psycho-Oncology, 2015, 24, 1761-1766.	1.0	20
58	Association between single nucleotide polymorphisms in the DNA repair gene LIG3 and acute adverse skin reactions following radiotherapy. Radiotherapy and Oncology, 2011, 99, 231-234.	0.3	18
59	Construction of tissue microarrays from core needle biopsies – a systematic literature review. Histopathology, 2016, 68, 323-332.	1.6	18
60	Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. World Journal of Surgical Oncology, 2006, 4, 44.	0.8	17
61	Treatment Strategies and Survival Outcomes in Breast Cancer. Cancers, 2020, 12, 735.	1.7	17
62	Preoperative endocrine therapy for breast cancer Endocrine-Related Cancer, 2000, 7, 131-141.	1.6	16
63	Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Endocrine-Related Cancer, 2006, 13, 251-255.	1.6	16
64	Peri-Operative Management of Older Adults with Cancer—The Roles of the Surgeon and Geriatrician. Cancers, 2015, 7, 1605-1621.	1.7	16
65	The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Research and Treatment, 2001, 67, 273-278.	1.1	15
66	Neoadjuvant chemotherapy in locally advanced primary breast cancers – The Nottingham experience. European Journal of Surgical Oncology, 2007, 33, 972-976.	0.5	15
67	The management of intrahepatic stones. Advances in Surgery, 1996, 29, 111-29.	0.6	15
68	Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Preference and Adherence, 2013, 7, 245.	0.8	14
69	Axillary reverse mapping in NO patients requiring sentinel lymph node biopsy – A systematic review of the literature and necessity of a randomised study. Breast, 2017, 33, 57-70.	0.9	14
70	Health-related quality of life from the FALCON phaseÂIII randomised trial of fulvestrant 500Âmg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 2018, 94, 206-215.	1.3	14
71	The care of older cancer patients in the United Kingdom. Ecancermedicalscience, 2020, 14, 1101.	0.6	14
72	Current status of breast cancer in Hong Kong. Chinese Medical Journal, 1997, 110, 474-8.	0.9	14

5

#	Article	IF	CITATIONS
73	Bone turnover markers in postmenopausal breast cancer treated with fulvestrant – A pilot study. Breast, 2009, 18, 204-207.	0.9	13
74	Current Challenges Faced by Cancer Clinical Trials in Addressing the Problem of Under-Representation of Older Adults: A Narrative Review. Oncology and Therapy, 2021, 9, 55-67.	1.0	13
75	The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK. Cancer Biology and Medicine, 2015, 12, 308-15.	1.4	13
76	The â€~other half' of breast cancer: A review of male breast cancer. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 406-413.	0.3	12
77	Risks of nonadherence to hormone therapy in Asian women with breast cancer. Kaohsiung Journal of Medical Sciences, 2015, 31, 328-334.	0.8	12
78	Liver Kinase B1—A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women. Cancers, 2019, 11, 149.	1.7	12
79	The predictive value of G8 and the Cancer and aging research group chemotherapy toxicity tool in treatment-related toxicity in older Chinese patients with cancer. Journal of Geriatric Oncology, 2021, 12, 557-562.	0.5	12
80	Pregnancy-related gigantomastia. Case report. Archives of Gynecology and Obstetrics, 1997, 259, 87-89.	0.8	11
81	The role of primary endocrine therapy in older women with operable breast cancer. Future Oncology, 2015, 11, 1555-1565.	1.1	11
82	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. Journal of Geriatric Oncology, 2021, 12, 848-850.	0.5	11
83	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Critical Reviews in Oncology/Hematology, 2009, 72, 76-82.	2.0	10
84	Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer. World Journal of Surgical Oncology, 2011, 9, 101.	0.8	10
85	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients. Annals of Oncology, 2014, 25, 837-842.	0.6	10
86	Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers. Minerva Chirurgica, 2003, 58, 297-303.	0.8	10
87	OMENTAL TRANSPOSITION FLAP FOR GROSS LOCALLY RECURRENT BREAST CANCER. ANZ Journal of Surgery, 1997, 67, 185-186.	0.3	9
88	Primary endocrine therapy in locally advanced breast cancers—the Nottingham experience. Breast Cancer Research and Treatment, 2009, 113, 403-407.	1.1	9
89	A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts. Breast Cancer Research and Treatment, 2014, 147, 671-674.	1.1	9
90	Controversial issues in the management of older adults with early breast cancer. Journal of Geriatric Oncology, 2017, 8, 397-402.	0.5	9

#	Article	IF	CITATIONS
91	The impact of breast cancer surgery on functional status in older women – A systematic review of the literature. European Journal of Surgical Oncology, 2021, 47, 1891-1899.	0.5	9
92	Concordance between core needle biopsy and surgical excision specimens for Kiâ€67 in breast cancer –â€ systematic review of the literature. Histopathology, 2022, 80, 468-484.	%a 1.6	9
93	Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?. Breast Cancer Research and Treatment, 2001, 65, 155-162.	1.1	8
94	Fulvestrant. Expert Opinion on Investigational Drugs, 2002, 11, 303-308.	1.9	8
95	A competing risk analysis of hormone therapy interruption in Asian women with breast cancer. Pharmacoepidemiology and Drug Safety, 2015, 24, 301-309.	0.9	8
96	Primary breast cancer in the elderly: a systematic literature review on histological type and clinical outcome. Future Oncology, 2015, 11, 259-265.	1.1	8
97	Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes. British Journal of Surgery, 2021, 108, 315-325.	0.1	7
98	Surgery versus primary endocrine therapy for elderly women with estrogen receptor-positive early operable primary breast cancer: Survival analysis and correlation with oestrogen receptor positivity. Journal of Clinical Oncology, 2009, 27, 612-612.	0.8	7
99	Challenges in Geriatric Oncology—A Surgeon's Perspective. Current Oncology, 2022, 29, 659-674.	0.9	7
100	A vision to optimise the management of primary breast cancer in older women. Breast, 2010, 19, 153-155.	0.9	6
101	Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer. Breast, 2014, 23, 567-572.	0.9	6
102	Preoperative hormone therapy trials for breast cancer. Breast, 2001, 10, 1-5.	0.9	5
103	Metastatic Carcinoma of the Breast with Tubular Features: Differences Compared with Metastatic Ductal Carcinoma of No Specific Type. Clinical Oncology, 2004, 16, 119-124.	0.6	5
104	Ruptured gallbladder as the first presentation of breast cancer. World Journal of Surgical Oncology, 2009, 7, 50.	0.8	5
105	Management of Operable Primary Breast Cancer in Older Women. Women's Health, 2014, 10, 405-422.	0.7	5
106	Tumour boards in geriatric oncology. Age and Ageing, 2018, 47, 168-170.	0.7	5
107	Treatment strategies and survival outcomes in older women with breast cancer: A comparative study between the FOCUS cohort and Nottingham cohort. Journal of Geriatric Oncology, 2018, 9, 635-641.	0.5	5
108	Observational cohort study to determine the degree and causes of variation in the rate of surgery or primary endocrine therapy in older women with operable breast cancer. European Journal of Surgical Oncology, 2021, 47, 261-268.	0.5	5

#	Article	IF	CITATIONS
109	Treatment choices for older women with primary operable breast cancer and cognitive impairment: Results from a prospective, multicentre cohort study. Journal of Geriatric Oncology, 2021, 12, 705-713.	0.5	5
110	Management of primary breast cancer in Hong Kong—can the guidelines be met?. European Journal of Surgical Oncology, 1999, 25, 255-260.	0.5	4
111	Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome. Cancers, 2021, 13, 1417.	1.7	4
112	Oestrogen receptor negative early operable primary breast cancer in older women—Biological characteristics and long-term clinical outcome. PLoS ONE, 2017, 12, e0188528.	1.1	4
113	Is surgery always indicated in older women with breast cancer?. Minerva Chirurgica, 2010, 65, 555-68.	0.8	4
114	Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. European Journal of Cancer, 2022, 172, 158-170.	1.3	4
115	Editorial comment on â€~Serum markers in breast cancer management'. European Journal of Cancer, 2002, 38, 1165-1166.	1.3	3
116	Approach to a Lump in the Breast: A Regional Perspective. Asian Journal of Surgery, 2005, 28, 65-70.	0.2	3
117	Care of the older woman with primary breast cancer: a sign of the times?. European Journal of Cancer Care, 2009, 18, 527-529.	0.7	3
118	Optimising the management of primary breast cancer in older women – A report of a multi-disciplinary study day. Breast, 2011, 20, 581-584.	0.9	3
119	Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome. Cancers, 2020, 12, 2067.	1.7	3
120	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers, 2020, 12, 712.	1.7	3
121	Primary endocrine therapy for early operable primary breast cancer in elderly women: A large series from a single institution. Journal of Clinical Oncology, 2009, 27, 630-630.	0.8	3
122	"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer. World Journal of Surgical Oncology, 2006, 4, 40.	0.8	2
123	A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report. World Journal of Surgical Oncology, 2008, 6, 132.	0.8	2
124	Patient pathway for breast cancer: turning points and future aspirations. Future Oncology, 2015, 11, 1059-1070.	1.1	2
125	The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review. Oncology and Therapy, 2020, 8, 231-250.	1.0	2
126	Biology of primary breast cancer in older women beyond routine biomarkers. Breast Cancer, 2021, 28, 991-1001.	1.3	2

#	Article	IF	CITATIONS
127	Pregnancy-related gigantomastia. Case report. Archives of Gynecology and Obstetrics, 1997, 259, 87-89.	0.8	2
128	Tamoxifen versus anastrozole as primary endocrine therapy in older women with early operable primary breast cancer Journal of Clinical Oncology, 2014, 32, e11533-e11533.	0.8	2
129	The care of older cancer patients in the United Kingdom. Ecancermedicalscience, 2020, 14, 1101.	0.6	2
130	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. Journal of Geriatric Oncology, 2022, , .	0.5	2
131	Palpable asymmetrical thickening of the breast: aclinical, radiological and pathological study. British Journal of Radiology, 2001, 74, 402-406.	1.0	1
132	Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast Cancer. American Journal of Cancer, 2002, 1, 293-300.	0.4	1
133	Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker. World Journal of Surgical Oncology, 2010, 8, 38.	0.8	1
134	Can age-related biology impact on clinical management and outcome of primary breast cancer in older women?. Future Oncology, 2016, 12, 1313-1316.	1.1	1
135	Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer, 2018, 25, 705-721.	1.6	1
136	The impact of tumour biology on the management of primary breast cancer in older women—based on a research programme in Nottingham. Annals of Breast Surgery, 0, 5, 5-5.	0.8	1
137	Does Breast Cancer Surgery Impact Functional Status and Independence in Older Patients? A Narrative Review. Oncology and Therapy, 2021, 9, 373-383.	1.0	1
138	Primary endocrine therapy with anastrozole for early operable primary breast cancer in the elderly: Early clinical and biological data. Journal of Clinical Oncology, 2006, 24, 10647-10647.	0.8	1
139	Differing pattern of biological characteristics of early operable primary breast cancer according to age Journal of Clinical Oncology, 2016, 34, e23272-e23272.	0.8	1
140	Special issues for older women with primary breast cancer. Breast Cancer Management, 2020, 9, .	0.2	1
141	Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. Journal of Clinical Oncology, 2006, 24, 680-680.	0.8	1
142	Relationships of cyclin E with clinical outcome and biomarkers in older women with early operable primary breast cancer Journal of Clinical Oncology, 2017, 35, e12031-e12031.	0.8	1
143	Baseline quality of life evaluation in older women with primary operable breast cancer and its relationship with different treatments Journal of Clinical Oncology, 2018, 36, e12601-e12601.	0.8	1
144	Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment. Journal of Clinical Oncology, 2004, 22, 536-536.	0.8	1

#	Article	IF	CITATIONS
145	A review of nipple discharge in Chinese women. Journal of the Royal College of Surgeons of Edinburgh, 1997, 42, 179-81.	0.1	1
146	Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer. Cost Effectiveness and Resource Allocation, 2022, 20, 9.	0.6	1
147	Primary Endocrine Therapy for Locally Advanced Breast Cancer—Is it an Inferior Approach? Experience from Nottingham. Indian Journal of Surgical Oncology, 2010, 1, 224-227.	0.3	0
148	A Continuing Mission to Optimize the Care of Older Women with Breast Cancer. Geriatrics (Switzerland), 2017, 2, 37.	0.6	0
149	O14 Optimising the management of primary breast cancer in older women. British Journal of Surgery, 2021, 108, .	0.1	0
150	American Society of Clinical Oncology 2021 Podcast: HR+, HER2â^' Breast Cancer. Oncology and Therapy, 2021, 9, 267-272.	1.0	0
151	The Estrogen and Progesterone Receptors. , 2010, , 21-42.		0
152	Relevance of rise in CA15.3 during fulvestrant therapy in advanced breast cancer patients Journal of Clinical Oncology, 2013, 31, e11567-e11567.	0.8	0
153	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: Biology and clinical outcome in comparison with younger (<70 years) patients Journal of Clinical Oncology, 2013, 31, e11608-e11608.	0.8	0
154	A pilot study exploring issues around decision making in older women with primary operable breast cancer Journal of Clinical Oncology, 2013, 31, e20588-e20588.	0.8	0
155	Intracellular intermolecular relationships of LKB1 in breast cancer Journal of Clinical Oncology, 2014, 32, 554-554.	0.8	0
156	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer Journal of Clinical Oncology, 2016, 34, e23283-e23283.	0.8	0
157	Short-term change in comprehensive geriatric assessment (CGA) scores following treatment of primary breast cancer in older women Journal of Clinical Oncology, 2016, 34, 10060-10060.	0.8	0
158	Biology and clinical outcomes of estrogen receptor positive (ER+) early primary breast cancer (BC) in older (≥70 years) women—A study based on core needle biopsies (CNB) Journal of Clinical Oncology, 2018, 36, e24253-e24253.	0.8	0
159	Early-Stage Breast Cancer in Older Adults. , 2019, , 1-10.		0
160	Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer Journal of Clinical Oncology, 2019, 37, 3128-3128.	0.8	0
161	Early-Stage Breast Cancer in Older Adults. , 2020, , 633-642.		0